Do Orally Ingested Collagen Peptides Reach the Eye

This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/do-orally-ingested-collagen-peptides-reach-the-eye

Test your visual field online: https://visualfieldtest.com

Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support

Excerpt:

Do Oral Collagen Supplements Reach the Eye? Many people take hydrolyzed collagen (collagen broken into small pieces) to support their joints, skin, and even eye health. Collagen is a structural protein found in the skin, bones, cartilage – and the eye’s connective tissues (like the cornea and sclera). A key question is whether collagen fragments eaten by mouth can travel through the body’s blood and actually get into eye tissues. This article reviews what we know about how collagen peptides behave in the body (their “pharmacokinetics”), whether small collagen pieces can cross the blood-aqueous and blood-retinal barriers, and what evidence animal or human studies provide. We also suggest how future experiments could directly test for collagen peptides in eye fluids and tissues. How Collagen Peptides Enter the Blood When you swallow hydrolyzed collagen (often from supplements or certain foods), your digestive system breaks it into very short chains of amino acids – mainly dipeptides and tripeptides (two or three amino acids linked together). Two common collagen dipeptides are Proline-Hydroxyproline (Pro-Hyp) and Hydroxyproline-Glycine (Hyp-Gly). These small peptides are unusually resistant to digestion because their amino acids (proline and hydroxyproline) form a rigid ring structure. Studies in humans show that after eating collagen hydrolysate, these collagen-derived peptides do appear in the blood. For example, Virgilio et al. (2024) gave people a collagen supplement and found high blood levels of Pro-Hyp, Hyp-Gly, and related collagen peptides within 1–2 hours (). In fact, they reported that “all collagen products yielded relevant plasma concentrations of the investigated metabolites” (meaning collagen breakdown products) (). In practical terms, this means that when you ingest collagen hydrolysate, enzymes in the gut produce a mix of small peptides (and free amino acids), some of which enter the bloodstream intact. The peak blood levels of peptides like Pro-Hyp typically occur around 60–120 minutes after ingestion, according to multiple studies (). After peaking, these peptide levels fall over the next few hours. For instance, one study found that Pro-Hyp (which contains the common hydroxyproline, 4Hyp) returned to its baseline (undetectable) level by about 4 hours after ingestion (). In contrast, a more unusual collagen peptide (Gly-3Hyp-4Hyp, containing 3-hydroxyproline and 4-hydroxyproline) stayed at its peak blood concentration through around 4 hours due to exceptional stability (). In summary, collagen peptides appear in the blood quickly and then are cleared within a few hours () (). What Happens to Collagen Peptides in the Body Once in circulation, collagen peptides distribute to various tissues. Animal tracer studies using radio-labeled collagen fragments show that ingested collagen tends to accumulate in collagen-rich tissues. For example, Kawaguchi et al. (2012) gave rats an oral dose of radioactively labeled Pro-Hyp and found it widely distributed in the body after 30 minutes. The highest radioactivity was in the digestive tract (stomach and intestines, understandable as the site of absorption) and surprisingly also in skin and cartilage – tissues built of collagen (). Cells like skin fibroblasts, cartilage cells, bone cells, and others that normally respond to collagen peptides actually took up these labeled fragments (). This suggests that after absorption, collagen peptides can travel through blood to reach collagen-containing tissues. Another rat study found that collagen tripeptides like Gly-Pro-Hyp remained in the blood and deposited mainly in the kidney (for excretion) and skin for days after dosing (). Importantly, these animal studies did not examine the eye. They show that collagen fragments in blood can end up in tissues with high collagen content (bone, cartilage, skin), but eyes were not tested. This leaves a data gap on whether any of the orally derived collagen peptides reach the eye. The Eye’s Protective Barriers Before considering if collagen peptides reach the eye, it helps to understand the eye’s blood-barrier systems. The eye has two major “blood-ocular” barriers: Blood-Aqueous Barrier (BAB): This is at the front of the eye (between the blood and the fluid in the front chamber called the aqueous humor). It is formed by the lining of the iris and ciliary body. The BAB restricts entry of many substances from the bloodstream into the anterior chamber (). Blood-Retinal Barrier (BRB): This is at the back of the eye (between blood and the retina/vitreous). The BRB is formed by tight junctions in the retinal blood vessels (inner BRB) and by the retinal pigment epithelium (outer BRB). It severely limits movement of molecules from the blood into the retina (). These barriers block large molecules (like most proteins) and many drugs. Only small, lipid-soluble, or actively transported molecules cross easily. In fact, drug delivery reviews stress that the BRB’s limited permeability is a major challenge for systemic eye treatments (). Could collagen peptides cross these barriers? Collagen peptides are small (di- or tri-peptides), but they are hydrophilic, so they usually would not passively diffuse through these barriers. However, the body does have specialized peptide transporters. In the gut and kidneys, transporters PepT1 and PepT2 carry di- and tri-peptides. There is evidence that similar carriers exist on ocular barriers. Notably, Atluri et al. (2004) showed in rabbits that a model dipeptide (glycylsarcosine) injected into the blood did reach the vitreous, retina, and aqueous humor within minutes (). The uptake was time-dependent and could be blocked by other peptides, indicating a carrier-mediated transport. In other words, the rabbit eye has peptide transporters at its blood barriers that can shuttle small peptides from blood into ocular fluids (). In summary, small collagen-derived dipeptides could cross into the eye if they fit those transporters. This has been shown with model substrates (like glycylsarcosine); natural collagen peptides like Pro-Hyp may also use the same pathways. However, direct evidence that oral collagen peptides enter the eye is still missing. What Studies Show (and Don’t Show) About Eye Uptake To date, no published human or animal study has directly measured collagen peptides in eye tissues or fluids after oral dosing. We have hints but no definitive tracking for the eye itself. The earliest evidence comes from the rabbit glycylsarcosine experiment (): it proves an oligopeptide can cross both anterior (blood-aqueous) and posterior (blood-retinal) barriers in healthy eyes. But glycylsarcosine is a simple model peptide, not derived from collagen. For actual collagen fragments, we only have general distribution studies (like Kawaguchi’s rat autoradiography ()). Those showed radioactivity in skin, cartilage, bone marrow, etc., but made no mention of eyes. It may mean the eye’s radioactivity was low or unmeasured, or simply not reported. If collagen peptides did not accumulate in the eye as much as in skin, the study might not have noted it. Because of the blood-ocular barriers, it seems unlikely that large fractions of orally ingested collagen peptides get into eye fluids. But we cannot rule it out. For example, any collagen peptides in the blood will eventually pass through the blood vessels of the choroid and iris; some fraction might slip through transporters into the sclera, retina, or aqueous. We just lack measurements. In short, evidence is very limited. No study has given people labeled collagen and then sampled their aqueous humor, vitreous, or optic nerve tissue to look for peptides. This is a key data gap. We can only infer from related work that entry is biochemically possible but probably low in quantity. Designing Experiments to Find Collagen Peptides in the Eye Future experiments could directly answer the question by measuring peptide levels in ocular compartments after tracer dosing. For example: Animal Tracer Studies: Give animals (e.g. rabbits or mice) collagen hydrolysate labeled with a heavy isotope or a radioactive tag (such as ^14C or ^3H on an amino acid). After dosing, at various times collect samples of aqueous humor (via needle tap), vitreous humor, and dissect tissues like the trabecular meshwork, sclera, retina, and optic nerve head. Measure radioactivity or use sensitive mass spectrometry to detect labeled peptides in those samples. Autoradiography (exposing eye sections to film) could visually show peptide distribution in ocular tissues. This would directly test if any collagen-derived peptides cross into the eye. Ocular Microdialysis: In larger animals (rabbits or dogs), tiny probes called microdialysis fibers can sample fluid from inside the eye over time. If animals are fed labeled collagen, the microdialysis samples from anterior or posterior chamber could be analyzed for labeled peptides. This technique has been used in ocular drug studies and could reveal time-courses of any peptide reaching the eye fluid. Human Surgical Sampling: Make use of eye operations to sample fluids. For example, prior to routine cataract surgery, a patient could take a dose of collagen hydrolysate containing a non-radioactive stable isotope label. Just before surgery, the surgeon

Transcript

SPEAKER_00 0:00

Do oral collagen supplements reach the eye? Many people take hydrolyzed collagen, collagen broken into small pieces, to support their joints, skin, and even eye health. Collagen is a structural protein found in the skin, bones, cartilage, and the eye's connective tissues, like the cornea and sclera. A key question is whether collagen fragments eaten by mouth can travel through the body's blood and actually get into eye tissues. This article reviews what we know about how collagen peptides behave in the body, their pharmacokinetics, whether small collagen pieces can cross the blood aqueous and blood retinal barriers, and what evidence animal or human studies provide. We also suggest how future experiments could directly test for collagen peptides in eye fluids and tissues. How collagen peptides enter the blood. When you swallow hydrolyzed collagen, often from supplements or certain foods, your digestive system breaks it into very short chains of amino acids, mainly dipeptides and tripeptides, two or three amino acids linked together. Two common collagen dipeptides are proline-hydroxyproline, prohype, and hydroxyproline glycine, hep gly. These small peptides are unusually resistant to digestion because their amino acids, proline and hydroxyproline, form a rigid ring structure. Studies in humans show that after eating collagen hydrolysate, these collagen-derived peptides do appear in the blood. For example, Virgilio et al. 2024 gave people a collagen supplement and found high blood levels of prohype, hype gly, and related collagen peptides within 1 to 2 hours. In fact, they reported that all collagen products yielded relevant plasma concentrations of the investigated metabolites, meaning collagen breakdown products. In practical terms, this means that when you ingest collagen hydrolysate, enzymes in the gut produce a mix of small peptides and free amino acids, some of which enter the bloodstream intact. The peak blood levels of peptides like prohype typically occur around 60 to 120 minutes after ingestion, according to multiple studies. After peaking, these peptide levels fall over the next few hours. For instance, one study found that prohype, which contains the common hydroxyproline 4-hype, returned to its baseline, undetectable, level by about four hours after ingestion. In contrast, a more unusual collagen peptide, gly3 hype 4-hype, containing 3-hydroxyproline and 4-hydroxyproline, stayed at its peak blood concentration through around 4 hours due to exceptional stability. In summary, collagen peptides appear in the blood quickly and then are cleared within a few hours. What happens to collagen peptides in the body? Once in circulation, collagen peptides distribute to various tissues. Animal tracer studies using radio labeled collagen fragments show that ingested collagen tends to accumulate in collagen-rich tissues. For example, Kawaguchi et al. gave rats an oral dose of radioactively labeled proHEP and found it widely distributed in the body after 30 minutes. The highest radioactivity was in the digestive tract, stomach and intestines, understandable as the site of absorption. And surprisingly, also in skin and cartilage, tissues built of collagen. Cells like skin fibroblasts, cartilage cells, bone cells, and others that normally respond to collagen peptides actually took up these labeled fragments. This suggests that after absorption, collagen peptides can travel through blood to reach collagen-containing tissues. Another rat study found that collagen tripeptides like GlyPro hype remained in the blood and deposited mainly in the kidney for excretion and skin for days after dosing. Importantly, these animal studies did not examine the eye. They show that collagen fragments in blood can end up in tissues with high collagen content, bone, cartilage, skin, but eyes were not tested. This leaves a data gap on whether any of the orally derived collagen peptides reach the eye. The eye's protective barriers. Before considering if collagen peptides reach the eye, it helps to understand the eye's blood barrier systems. The eye has two major blood ocular barriers. Blood aqueous barrier, BAB. This is at the front of the eye, between the blood and the fluid in the front chamber called the aqueous humor. It is formed by the lining of the iris and ciliary body. The BIB restricts entry of many substances from the bloodstream into the anterior chamber. Blood retinal barrier, BRB. This is at the back of the eye, between blood and the retina vitreus. The BRB is formed by tight junctions in the retinal blood vessels, inner BRB, and by the retinal pigment epithelium, outer BRB. It severely limits movement of molecules from the blood into the retina. These barriers block large molecules, like most proteins and many drugs. Only small, lipid-soluble or actively transported molecules cross easily. In fact, drug delivery reviews stress that the BRB's limited permeability is a major challenge for systemic eye treatments. Could collagen peptides cross these barriers? Collagen peptides are small, di or tripeptides, but they are hydrophilic, so they usually would not passively diffuse through these barriers. However, the body does have specialized peptide transporters. In the gut and kidneys, transporters Pepti1 and Pepti2 carry di and tripeptides. There is evidence that similar carriers exist on ocular barriers. Notably, at Luri et al. 2004, showed in rabbits that a model dipeptide, glycylsarcosine, injected into the blood did reach the vitreous, retina, and aqueous humor within minutes. The uptake was time-dependent and could be blocked by other peptides, indicating a carrier-mediated transport. In other words, the rabbit eye has peptide transporters at its blood barriers that can shuttle small peptides from blood into ocular fluids. In summary, small collagen-derived dipeptides could cross into the eye if they fit those transporters. This has been shown with model substrates like glycosarcosine, natural collagen peptides like prohype may also use the same pathways. However, direct evidence that oral collagen peptides enter the eye is still missing. What studies show and don't show about eye uptake. To date, no published human or animal study has directly measured collagen peptides in eye tissues or fluids after oral dosing. We have hints, but no definitive tracking for the eye itself. The earliest evidence comes from the rabbit glycosarcosine experiment. It proves an oligopeptide can cross both anterior blood aqueous and posterior blood retinal barriers in healthy eyes. But glycalcosine is a simple model peptide, not derived from collagen. For actual collagen fragments, we only have general distribution studies, like Kawaguchi's rat autoradiography. Those showed radioactivity in skin, cartilage, bone marrow, etc., but made no mention of eyes. It may mean the eye's radioactivity was low or unmeasured, or simply not reported. If collagen peptides did not accumulate in the eye as much as in skin, the study might not have noted it. Because of the blood ocular barriers, it seems unlikely that large fractions of orally ingested collagen peptides get into eye fluids. But we cannot rule it out. For example, any collagen peptides in the blood will eventually pass through the blood vessels of the choroid and iris. Some fraction might slip through transporters into the sclera, retina, or aqueous. We just lack measurements. In short, evidence is very limited. No study has given people labeled collagen and then sampled their aqueous humor, vitreous, or optic nerve tissue to look for peptides. This is a key data gap. We can only infer from related work that entry is biochemically possible, but probably low in quantity. Designing experiments to find collagen peptides in the eye. Future experiments could directly answer the question by measuring peptide levels in ocular compartments after tracer dosing. For example, animal tracer studies give animals, e.g., rabbits or mice, collagen hydrolysate labeled with a heavy isotope or a radioactive tag, such as 14C or 3H on an amino acid. After dosing, at various times collect samples of aqueous humor via needle tap, vitreous humor, and dissect tissues like the trabecular meshwork, sclera, retina, and optic nerve head. Measure radioactivity or use sensitive mass spectrometry to detect labeled peptides in those samples. Autoradiography, exposing eye sections to film, could visually show peptide distribution in ocular tissues. This would directly test if any collagen-derived peptides cross into the eye. Ocular microdialysis. In larger animals, rabbits or dogs, tiny probes called microdialysis fibers can sample fluid from inside the eye over time. If animals are fed labeled collagen, the microdialysis samples from anterior or posterior chamber could be analyzed for labeled peptides. This technique has been used in ocular drug studies and could reveal time courses of any peptide reaching the eye fluid. Human surgical sampling. Make use of eye operations to sample fluids. For example, prior to routine cataract surgery, a patient could take a dose of collagen hydrolysate containing a non-radioactive stable isotope label. Just before surgery, the surgeon could remove a small amount of aqueous humor, a common practice to manage pressure. That fluid could be analyzed by mass spectrometry to see if labeled collagen peptides are present. Similarly, donor eyes from patients, with consent, could be tested for peptide content. Cell and tissue models, in vitro studies using human ocular cells of the iris, retina, or trabecular meshwork, could test uptake of labeled peptides across a basement membrane model of the blood barriers. While not directly in humans, such models help show if collagen peptides can penetrate ocular barrier cells. Each of these designs would need careful controls, e.g., measuring blood levels too, and sensitive analytical methods, LCMS, to quantify tiny peptide amounts, but they are technically feasible. Together, they could fill the current knowledge gap. Conclusion In summary, orally ingested collagen hydrolysate does yield small collagen peptides in the bloodstream. These peptides reach peak blood levels within an hour or two and are mostly cleared by about 4 to 6 hours. Some peptides are very stable and linger longer, e.g., Gly3 hype 4 hype. Animal studies confirm that collagen peptides distribute to collagen-rich tissues like skin and cartilage. The eye, however, is protected by blood ocular barriers that normally keep most blood-borne molecules out. A model experiment showed dipeptides can cross these barriers in rabbits, but we lack direct data for oral collagen peptides entering human eye fluids or tissues. No published study has measured collagen peptides in the aqueous humor or retina after oral collagen intake. Therefore, the question is still unresolved. It remains unknown whether taking collagen supplements significantly increases collagen-derived peptides in the eye. The evidence to date suggests only small amounts, if any, might cross into eye compartments. Solving this will require targeted tracer experiments or clinical sampling, as outlined above. Until then, scientists can only say that collagen peptides reach the bloodstream, but whether they reach the eye in meaningful levels remains to be demonstrated. Sources, collagen peptide absorption, and blood levels have been documented in human studies. Reviews of ocular barriers note that passage of molecules is highly restricted, though a rabbit study showed dipeptides can use an oligopeptide transporter to enter eye fluids. Animal tracer studies have shown collagen-derived radioactivity in skin and cartilage, but do not report eye data. No existing study has directly measured collagen peptides in authentic ocular tissues or fluids, indicating a clear gap in research. All links to sources are available in the text version of this article. You can find the full article at visualfieldtest.com. Thanks for listening. To check your visual field, click the link at the bottom of this article or visit visualfieldtest.com.